Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Power3 discovers biomarkers for early detection of breast cancer
Scientists at Power3 believe that they will be able to make this diagnosis by monitoring the blood serum concentrations of these proteins and then subjecting the results to
Scientists at Power3 believe that they will be able to make this diagnosis by monitoring the blood serum concentrations of these proteins and then subjecting the results to
“While having missed the primary endpoints will make for a challenging review with the agencies, we are committed to conducting a study to try to confirm the survival
The drug was withdrawn amid concerns around the deaths of 20 people who were taking the drug. However, the suspension will now be lifted after Health Canada accepted
Nevanac suspension contains a novel prodrug that rapidly penetrates ocular tissues. It is the first ophthalmic non-steroidal anti-inflammatory prodrug to receive FDA approval. Alcon expects Nevanac suspension to
Icoria will use its metabolomics platform to characterize differences in biochemical profiles between treated and untreated animal subjects and to identify those biochemicals that are specifically affected by
Firm approval of Caraco’s amended new drug application for zolpidem tartrate, 5mg and 10mg tablets, is anticipated after the patent for Sanofi-Aventis’ Ambien brand expires in October 2006.
Dr Yves Horsmans, Professor at Cliniques Universitaires St Luc in Brussels and principal investigator of the study commented. “These results create strong interest in clinical evaluation of ANA975,
GFI Clinical Services an 80-bed facility based in Evansville, Indiana, will now be part of Covance Clinical Research Unit Inc, and will be known as Covance GFI Research.
On the basis of their data, the researchers are proposing a new hypothesis that suggests that Alzheimer’s disease may be due to abnormalities in the regions of the
The Canadian regulatory agency has agreed to give the study the go-ahead, following Cel-Sci’s application submitted last month. The company hopes to recruit about 500 patients worldwide in